{"nctId":"NCT03725384","briefTitle":"Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia","startDateStruct":{"date":"2019-01-04","type":"ACTUAL"},"conditions":["Anemia","Iron Deficiency Anemia"],"count":51,"armGroups":[{"label":"Ferrous Sulfate and Vitamin C every other day","type":"EXPERIMENTAL","interventionNames":["Drug: Ferrous Sulfate 300Mg Tablet","Drug: Vitamin C 500Mg tablet"]},{"label":"Ferrous Sulfate and Vitamin C daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ferrous Sulfate 300Mg Tablet","Drug: Vitamin C 500Mg tablet"]}],"interventions":[{"name":"Ferrous Sulfate 300Mg Tablet","otherNames":["Iron","Oral iron"]},{"name":"Vitamin C 500Mg tablet","otherNames":["Ascorbic acid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 16 years;\n* Outpatients with iron deficiency anemia defined as Hb less than 120 g/L in women or 130g/L in men; AND ferritin less than 30 mcg/L\n\nExclusion Criteria:\n\n* • Pregnancy\n\n  * Currently breastfeeding\n  * Known history of inflammatory bowel disease\n  * Known history of celiac disease\n  * Known history of thalassemia or thalassemia trait\n  * Known inherited bleeding disorder\n  * Known intolerance or lack of response to oral ferrous gluconate, sulfate or fumarate in the last 12 weeks\n  * Multivitamin and mineral supplements (35 mg or more of elemental iron per day) in the 2 weeks prior to randomization\n  * Allergy to oral iron\n  * Allergy to any of the following medicinal and non-medicinal ingredients in ferrous sulfate: ferrous sulphate, calcium citrate, crospovidone, FD\\&C Red #40-Aluminum lake, FD\\&C Yellow #6-Aluminum Lake, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, purified water, talc titanium dioxide\n  * Allergy to any of the following medicinal and non-medicinal ingredients in vitamin C: Ascorbic acid, Colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and stearic acid\n  * Intravenous iron therapy in the past 12 weeks\n  * On anticoagulant therapy (e.g. warfarin, apixaban, dabigatran, edoxaban, rivaroxaban) initiated in the past 6 months\n  * Surgery planned in upcoming 12 weeks\n  * Chemotherapy planned in upcoming 12 weeks\n  * Blood donation planned in upcoming 12 weeks\n  * Previously enrolled in the study\n  * Creatinine clearance less than 30 mL/min\n  * Hemoglobin less than 80 g/L with active bleeding (defined as WHO grade 2 bleeding or higher in the past week)","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Feasibility of Enrolling Patients in the Trial","description":"Enrollment in the trial will be defined as documentation of informed consent for patients approached. The primary outcome of this study is the feasibility of enrolling 52 participants in the trial over a 2-year period. Eligibility based on lab criteria was determined after consent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Eligible Participants Consenting","description":"Proportion of eligible patients after initial inclusion/exclusion screening that consent to participating in the study. Eligibility based on lab criteria was determined after consent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Receiving the Allocated Treatment","description":"Proportion of patients who signed informed consent and received the allocated treatment they were randomly assigned to.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Completing Laboratory Tests","description":"Proportion of treated patients who completed both 4 week and 12 week laboratory tests","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null},{"groupId":"OG001","value":"0.81","spread":null},{"groupId":"OG002","value":"0.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Treated Patients Completing Side Effect Questionnaire at Week 4, 8 and 12","description":"Proportion of treated patients completing 4 week, 8 week and 12 week side effect questionnaire","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null},{"groupId":"OG001","value":"0.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Completing FACIT-fatigue Scale","description":"Proportion of patients who received treatment and completed 4 week, 8 week and 12 week FACIT-fatigue scale","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null},{"groupId":"OG001","value":"0.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence to Treatment","description":"Adherence was measured by the proportion of treated patients who took at least 90% of their prescribed doses","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":null},{"groupId":"OG001","value":"0.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Treated Patients Requiring a Step Down in Therapy","description":"Proportion of treated patients requiring a step down in therapy by Week 4 and Week 12 (same proportions at both time points).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemoglobin Increment","description":"Hemoglobin increment at 4 and 12 weeks is defined as the 4 or 12 week hemoglobin value minus the baseline hemoglobin value","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":"13"},{"groupId":"OG001","value":"110","spread":"10"},{"groupId":"OG002","value":"110","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":"7"},{"groupId":"OG001","value":"119","spread":"10"},{"groupId":"OG002","value":"121","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":"9"},{"groupId":"OG001","value":"126","spread":"8"},{"groupId":"OG002","value":"129","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Proportion With Complete Hemoglobin Response","description":"Proportion with complete hemoglobin response defined as hemoglobin greater than or equal to 120 g/L in women; and 130 g/L in men at 4 weeks and 12 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Reticulocyte Count","description":"Change in reticulocyte count at 4 and 12 weeks defined as the 4 or 12 week reticulocyte count minus the baseline reticulocyte count","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Ferritin at 12 Weeks","description":"Change in ferritin at 12 weeks, defined as the value at 12 weeks minus the baseline value.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Iron at 12 Weeks","description":"Change in serum iron at 12 weeks defined as the value at 12 weeks minus the baseline value","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in TSAT at 12 Weeks","description":"Change in transferrin saturation (TSAT) at 12 weeks defined as the value at 12 weeks minus the baseline value. Interquartile range represents Q1 (25th percentile) to Q3 (75th percentile)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"FACIT-fatigue Score at 4, 8 and 12 Weeks","description":"Quality of life (FACIT-fatigue scale) at 4, 8 and 12 weeks. Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue scale.\n\nOn this scale, lower scores indicate better symptoms and higher scores represent worse symptoms. The FACIT-fatigue scale has a range from 0 to 52.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"9.8"},{"groupId":"OG001","value":"26.3","spread":"9.7"},{"groupId":"OG002","value":"25.2","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"8.5"},{"groupId":"OG001","value":"24.9","spread":"11.4"},{"groupId":"OG002","value":"23.4","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"8.5"},{"groupId":"OG001","value":"21.9","spread":"9.9"},{"groupId":"OG002","value":"21.0","spread":"9.3"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Side Effects at 4, 8 and 12 Weeks","description":"Proportion of patients with side effects at 4, 8 and 12 weeks, as determined by the oral iron side effect questionnaire","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null},{"groupId":"OG001","value":"0.56","spread":null},{"groupId":"OG002","value":"0.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.48","spread":null},{"groupId":"OG002","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.44","spread":null},{"groupId":"OG002","value":"0.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Stopped Oral Iron Due to Side Effects","description":"Number of patients who discontinued oral iron therapy due to side effects by week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients in Need of Escalation Therapy","description":"Need for escalation in therapy (increase in oral iron regimen from every other day to daily, need for intravenous iron, need for transfusion, visit to emergency department related to anemia) assessed at 12 weeks","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With a Drop in Hemoglobin at Weeks 4 and 12","description":"Proportion of patients with a drop in hemoglobin of 10 g/L or more at weeks 4 and 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Types of Adverse Effects at 4 Weeks","description":"Proportion of patients with each type of adverse event at week 4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.26","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.26","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.26","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.30","spread":null},{"groupId":"OG002","value":"0.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.19","spread":null},{"groupId":"OG002","value":"0.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.19","spread":null},{"groupId":"OG002","value":"0.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"0.11","spread":null},{"groupId":"OG002","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Constipation","Nausea","Headache","Breathlessness","Heartburn"]}}}